Rhythm Pharmaceuticals, Inc. (RYTM) insider trading.
In Q3 2026, insiders at Rhythm Pharmaceuticals, Inc. reported 28 non-derivative transactions on 9 Forms 3, 4 and 5: 0 open-market purchases and 20 sales worth $28.8M.
- Transactions
- 28
- Purchases (P)
- 0
- Sales (S)
- 20
- Net shares, P minus S
- -258,450
- Insiders
- 6
- Last filed
- 2026-09-14
Insiders
| Insider | Relationship | Transactions | Buys | Sales |
|---|---|---|---|---|
| Mazabraud Yann | Officer · EVP, Head of International | 7 | 0 | 6 |
| Meeker David P | Director, Officer · President and CEO | 6 | 0 | 5 |
| Garfield Alastair | Officer · Chief Scientific Officer | 6 | 0 | 4 |
| Smith Hunter C | Officer · Chief Financial Officer | 4 | 0 | 3 |
| Lee Jennifer Kayden | Officer · EVP, Head of North America | 3 | 0 | 1 |
| Shulman Joseph | Officer · Chief Technical Officer | 2 | 0 | 1 |
Transactions
| Date | Insider | Code | Shares | Price | Owned after | Filing |
|---|---|---|---|---|---|---|
| 2026-09-14 | Meeker David P | S (D) | 2,300 | $105.19 | 239,258 | Form 4 |
| 2026-09-14 | Meeker David P | S (D) | 6,439 | $101.75 | 282,819 | Form 4 |
| 2026-09-14 | Meeker David P | S (D) | 30,746 | $102.35 | 252,073 | Form 4 |
| 2026-09-14 | Meeker David P | S (D) | 8,698 | $103.43 | 243,375 | Form 4 |
| 2026-09-14 | Meeker David P | S (D) | 1,817 | $104.55 | 241,558 | Form 4 |
| 2026-09-14 | Meeker David P | M (A) | 50,000 | $6.05 | 289,258 | Form 4 |
| 2026-08-31 | Smith Hunter C | S (D) | 11,514 | $105.37 | 142,212 | Form 4 |
| 2026-08-31 | Smith Hunter C | S (D) | 23,072 | $104.59 | 153,726 | Form 4 |
| 2026-08-31 | Smith Hunter C | M (A) | 57,187 | $25.79 | 176,798 | Form 4 |
| 2026-08-31 | Smith Hunter C | S (D) | 28,188 | $106.2 | 114,024 | Form 4 |
| 2026-08-13 | Garfield Alastair | S (D) | 1,556 | $117.08 | 6,495 | Form 4 |
| 2026-08-13 | Garfield Alastair | S (D) | 800 | $119.17 | 2,295 | Form 4 |
| 2026-08-13 | Garfield Alastair | S (D) | 2,007 | $116.11 | 8,051 | Form 4 |
| 2026-08-13 | Garfield Alastair | S (D) | 3,400 | $118.28 | 3,095 | Form 4 |
| 2026-08-13 | Shulman Joseph | S (D) | 5,079 | $119.75 | 15,915 | Form 4 |
| 2026-08-13 | Shulman Joseph | M (A) | 2,024 | $6.8 | 20,994 | Form 4 |
| 2026-08-13 | Lee Jennifer Kayden | S (D) | 75,834 | $117.38 | 0 | Form 4 |
| 2026-08-13 | Lee Jennifer Kayden | M (A) | 35,000 | $24.29 | 54,233 | Form 4 |
| 2026-08-13 | Lee Jennifer Kayden | M (A) | 21,601 | $6.8 | 75,834 | Form 4 |
| 2026-08-12 | Mazabraud Yann | S (D) | 14,568 | $115.43 | 91,182 | Form 4 |
| 2026-08-12 | Mazabraud Yann | S (D) | 18,208 | $116.49 | 72,974 | Form 4 |
| 2026-08-12 | Mazabraud Yann | S (D) | 17,319 | $117.47 | 55,655 | Form 4 |
| 2026-08-12 | Mazabraud Yann | S (D) | 1,000 | $112.86 | 109,355 | Form 4 |
| 2026-08-12 | Mazabraud Yann | S (D) | 2,300 | $111.8 | 110,355 | Form 4 |
| 2026-08-12 | Mazabraud Yann | M (A) | 46,625 | $6.8 | 112,655 | Form 4 |
| 2026-08-12 | Mazabraud Yann | S (D) | 3,605 | $114.7 | 105,750 | Form 4 |
| 2026-07-01 | Garfield Alastair | M (A) | 4,445 | — | 12,208 | Form 4 |
| 2026-07-01 | Garfield Alastair | F (D) | 2,150 | $110.41 | 10,058 | Form 4 |
Transaction codes in this quarter
Get RYTM insider transactions through the API
curl "https://sec-api.dev/api/v1/insider-transactions?period=2026q3&cik=1649904&limit=100" \
-H "Authorization: Bearer $SEC_API_KEY"Insider trading API guide · RYTM company page · Rhythm Pharmaceuticals, Inc. on SEC.gov
Questions
Are insiders buying or selling Rhythm Pharmaceuticals, Inc. (RYTM)?
In Q3 2026, insiders at Rhythm Pharmaceuticals, Inc. reported 28 non-derivative transactions on 9 Forms 3, 4 and 5: 0 open-market purchases and 20 sales worth $28.8M. Grants, tax withholding and option exercises are counted as transactions but are not purchases or sales.
Where do these Rhythm Pharmaceuticals, Inc. insider trades come from?
From the SEC Insider Transactions Data Sets for Q3 2026, which republish the Forms 3, 4 and 5 filed on EDGAR. Each row links to its filing on SEC.gov.
Plain-text version for agents and LLMs: /insider-trading/rytm.md
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.